ClinicalTrials.gg
Enrolling by invitationNCT05738798ORKA-NLUpdated Sep 16, 2025

Oral Immunotherapy in Young Children With Food Allergy

An interventional study of oral immunotherapy in Food Allergy, sponsored by Deventer Ziekenhuis. Enrolling by invitation at 4 sites in Netherlands. Open to participants aged 9 Months to 30 Months. Per ClinicalTrials.gov, last updated 2025-09-16.

Sponsored by Deventer Ziekenhuis · Not applicable, Interventional, and Treatment

How we know

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Enrollment
500
Allocation
Randomized
Ages
9 Months to 30 Months
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-21

Among 12 studies in Food Hypersensitivity with a site in Netherlands — 2 open to participants now, 4 under way, 2 of them phase 3. Food Hypersensitivity · Netherlands.

Planned enrollment
2nd of 11
500 · median 171
Started
2023
with 3 others
No phase
4 of 12
2 open now
Registered
8th of 12
by date
Lead sponsor
1 of 12
Deventer Ziekenhuis

Among the 12 studies in Food Hypersensitivity with a site in Netherlands, this one is the 2nd largest by planned enrollment of the 11 interventional ones that give a count, is one of 4 that started in 2023, is one of 4 with no phase, and was the 8th registered.

Food Hypersensitivity

378 studies on the registry are indexed under Food Hypersensitivity; 90 are open to participants now.

Browse Food Hypersensitivity studies →

Open to participants now

2 of the 12 studies in Food Hypersensitivity with a site in Netherlands are open now. Recruiting first, the newest first:

All 2 open studies →

A study can be open while its sites in Netherlands have not opened yet or have stopped. Only those recruiting at a site in Netherlands →

Who these studies take

Of the 53 Food Hypersensitivity studies recruiting now, 8 (15%) set no upper age limit and 41 (77%) stop at 75 or younger; 45 take children under 18; 17 take healthy volunteers.

This study: 9 Months to 30 Months · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 12 studies in Food Hypersensitivity with a site in Netherlands, or all of them as a file.
02

Study summary

The goal of this clinical trial is to learn about oral immunotherapy in food allergic children \< 30 months of age. The main question it aims to answer is: What is the clinical- and cost-effectiveness of early low-dose oral immunotherapy aimed at long-term tolerance induction. Participants will receive oral immunotherapy for 1 year with a maintenance dose of 300 mg allergenic protein and are compared with food allergic infants not receiving oral immunotherapy to compare with natural tolerance development.

Read the detailed description

Primary objective: What is the clinical- and cost-effectiveness of early low-dose oral immunotherapy aimed at long-term tolerance induction in children under the age of 30 months with an established food allergy compared to routine care? Secondary objective: What is the effect of early low-dose oral immunotherapy in children under the age of 30 months with an established food allergy on (allergy specific) quality of life of parents and children compared to routine care? Study design: randomized controlled superiority trial Study population: Children between 9 and 30 months old with an IgE-mediated food allergy to peanut, tree nuts, cow's milk and/or hen's egg as proven by an oral food challenge. Intervention: 1-year low-dose oral immunotherapy (daily 300 mg allergenic protein) compared to strict avoidance in the control group.

Main study parameters/endpoints: Long-term tolerance as assessed by an exit oral food challenge at 4 weeks after discontinuation of the oral immunotherapy, combined with uncomplicated consumption of a full dose of the specific food at 6 months after discontinuation of the therapy.

03

Conditions studied

  • Food Allergy

Browse trials for

Keywords

  • Oral immunotherapy
  • infants
  • food allergy
04

Who can participate

Ages eligible
9 Months to 30 Months
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • An IgE-mediated food allergy to peanut, cashew, hazelnut, walnut, cow's milk and/or hen's egg as proven by sensitization to the specific allergen (sIgE > 0.35kU/l) and a positive oral food challenge.
  • The fore-mentioned allergens are introduced into the diet of the child (the child is tolerant for the specific allergen(s)), or the child is diagnosed with a food allergy for the specific allergen(s).

Exclusion criteria

Exclusion Criteria:

  • (Suspected) eosinophilic oesophagitis
  • Uncontrolled asthma/ viral wheeze.
  • The inability of parents to follow instructions, recognize allergic reactions or administer emergency medication.
  • Participation in any other intervention study at the time of the OIT study, with the exception of studies on guided early introduction of highly allergenic foods.
05

Study design

Phase
Not applicable
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
500 participants (estimated)

Study arms

  • Experimental
    oral immunotherapy

    oral immunotherapy, maintenance phase with daily 300 mg allergenic protein during 1 year

    Dietary Supplement: oral immunotherapy

  • No intervention
    routine care

    strictly avoidance of the specific allergenic food

Interventions

  • Dietary supplementoral immunotherapy

    oral immunotherapy is performed by freely available, widely used food products, regularly part of a normal infant's diet such as peanut butter or boiled egg.

06

What researchers measure

Primary outcomes

  1. Percentage of patients with sustained unresponsiveness to consumption of a specific allergenic food 4 weeks after stopping the 1-year oral immunotherapy (OIT)

    Definition of sustained unresponsiveness: a participant who passed an oral food challenge (OFC) to 4.2 gram of the allergenic protein. Definition of the allergenic protein: the allergenic protein which induced an allergic response at an OFC at the start of the study, and was administered to the patient during the OIT (i.e. milk, egg, peanut, hazelnut, cashew or walnut).

    Time frame: Timing of the OFC: week 57 (52 weeks of OIT, followed by a 4-week allergenic food-free interval)

  2. Percentage of tolerant participants at week 78

    In children achieving sustained unresponsiveness (outcome 1), the allergen is introduced into the diet by parents at a regular base. Six months after discontinuation of the OIT, tolerance to the specific allergenic protein is assessed. Definition of tolerant: Percentage of children with uncomplicated (i.e. without any allergic symptoms) consumption at home of a full dose of the specific allergenic protein (e.g. a glass of milk or a sandwich with peanut butter).

    Time frame: week 78 = 6 months after stop of the 1-year oral immunotherapy

  3. Cost-effectiveness ratio at 18 months (week 78).

    Incremental cost-effectiveness ratio (ICER) at 18 months (week 78). Costs associated with oral immunotherapy will be measured in Euros. Effectiveness will be considered as percentage of tolerant participants at week 78.

    Time frame: 18 months (week 78).

  4. Cost-utility ratio at 18 months (week 78).

    Incremental cost-utility ratio (ICUR) will be calculated for both groups using health-related quality of life (HRQoL) scores from the AQoL-6D (assessment of quality of life - 6 dimensions) and converted to utility scores and will be expressed in euros per QALY.

    Time frame: 18 months (week 78): at the end of the study period.

Secondary outcomes

  1. Health related quality of life of children, during the 1-year OIT and six months after the therapy (week 78)

    Children's quality of life as measured by: \- Food Allergy Quality of Life Questionnaire - parental form (FAQLQ-PF) This questionnaire consists of 14 questions to be answered on a 7-point Likert-scale. Minimum score is 0 points (no impact of food allergy on quality of life), maximum score is 84 (high impact of food allergy on quality of life)

    Time frame: during oral immunotherapy (T=0, 26 weeks and 52 weeks), and 6 months after stopping the oral immunotherapy (78 weeks)

  2. Occurrence of Adverse Event(s) Related to Oral Immunotherapy up to 65 weeks study participation

    (Serious) adverse events related to oral immunotherapy

    Time frame: during build-up (up to 3 months) and 1-year oral immunotherapy, total 65 weeks

  3. Levels of allergy-related immune parameters

    Levels of allergen specific IgE and IgG4

    Time frame: at start of the therapy and after 6 and 12 months maintenance therapy

  4. adherence

    Rate of daily providing the oral immunotherapy

    Time frame: during 1 year oral immunotherapy

  5. Health related quality of life of parents, during the 1-year OIT and six months after the therapy (week 78)

    Parental quality of life as measured by: \- Food Allergy Quality of Life- Parental Burden (FAQL-PB) This questionnaire consists of 17 questions to be answered on a 7-point Likert-scale. Minimum score is 0 points (no parental burden), maximum score is 102 (severe parental burden)

    Time frame: during oral immunotherapy (T=0, 26 weeks and 52 weeks), and 6 months after stopping the oral immunotherapy (78 weeks)

07

Study locations

4 sites
08

References and documents

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

Individual participant data

Plan to share: Yes — Data collected for this study will be stored in SPSS and Excel and analyzed in SPSS. Access to trial IPD can be requested after the study is completed by qualified researchers engaging in independent scientific research, and will be provided following review and approval of a research proposal and Statistical Analysis Plan (SAP) and execution of a Data Sharing Agreement (DSA). For more information or to submit a request, please contact wetenschapsbureau@dz.nl

Supporting information: Study protocol, Statistical analysis plan, Clinical study report

Time frame: 01-07-2025 - 01-07-2026

Access criteria: Researchers wanting to use the data would have to contact the PIs with a research proposal and Statistical Analysis Plan (SAP).

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Feb 2023 (actual). Primary completion is estimated for Aug 2026, 42 months after the start.

Of 82 non-industry interventional studies with no phase under Food Hypersensitivity, half reached primary completion within 29 months of starting (the median), counting those still running; a quarter within 13 and three quarters within 50. This study's planned 42 months is above that.

Counting every sponsor, half of 86 studies reached it within 30 months; a quarter within 13 and three quarters within 50.

How these figures are worked out, and which studies are left out of them.

Registered
Dec 20, 2022
First posted
Feb 22, 2023
StartActual
Feb 1, 2023
Primary completionEst.
Aug 30, 2026
CompletionEst.
May 1, 2027
Last update
Sep 16, 2025
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Sep 16, 2025, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT05738798
Lead sponsor
Deventer Ziekenhuis
Collaborators
Dutch National Health Care Institute, University of Twente, Utrecht University
Responsible party
Ted Klok (Principal Investigator, Deventer Ziekenhuis) — Principal investigator
First posted
Feb 22, 2023
Start date
Feb 1, 2023
Primary completion
Aug 30, 2026 (estimated)
Completion
May 1, 2027 (estimated)
Last update
Sep 16, 2025

Study contacts

Ted Klok, MD PhD
principal investigator · Deventer Ziekenhuis

Oversight

Data monitoring committee
Yes
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

No contact was published for this record. The registry link below has the sponsor’s details.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion